AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27284585 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-fluoride varnish (CHX-F)
Number of subjects: 57
Study 27284585 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine-thymol varnish (CHX-T)
Number of subjects: 57
Study 23963269 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes with low back pain
Number of subjects: 44
Study 23963269 — intervention group
Group type: COMPARATOR
Intervention: Healthy athletes (control group)
Number of subjects: 44
Study 22578254 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (215 μg/kg)
Number of subjects: 17
Study 22578254 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin (50 mg)
Number of subjects: 17
Study 22578254 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (215 μg/kg) + Ketanserin (50 mg)
Number of subjects: 17
Study 22578254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 20360777 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 615
Study 18635480 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope (GVL)
Number of subjects: 70
Study 18635480 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 70
Study 16491671 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen consumers
Number of subjects: 98
Study 16491671 — intervention group
Group type: COMPARATOR
Intervention: Nonconsumers
Number of subjects: 98
Study 12431855 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 36
Study 12431855 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 36
Study 12431855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10325291 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 108
Study 10325291 — intervention group
Group type: COMPARATOR
Intervention: Immediate dilatation and curettage
Number of subjects: 108
Study 10325291 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management with detectable pulsatile blood flow
Number of subjects: 108
Study 10325291 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management with no detectable flow
Number of subjects: 108
Study 9191511 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily beta‐blocker therapy (oral atenolol, 50 to 200 mg)
Number of subjects: 7500
Study 9191511 — intervention group
Group type: COMPARATOR
Intervention: Once daily calcium channel blocker therapy (oral diltiazem 120 to 360 mg)
Number of subjects: 7500
Study 1888800 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine therapy
Number of subjects: 18
Study 1888800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1888800 — intervention group
Group type: COMPARATOR
Intervention: Passive viewing task (GAD patients)
Number of subjects: 18
Study 1888800 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vigilance task (GAD patients)
Number of subjects: 18
Study 30262570 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (enoxaparin)
Number of subjects: 949
Study 30262570 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin
Number of subjects: 949
Study 30262570 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 949
Study 29710062 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based resistance exercise program
Number of subjects: 40
Study 29710062 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 27955680 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk This Way (WTW) intervention
Number of subjects: 0
Study 27955680 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 0
Study 24463121 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (with medications and exercise prescription)
Number of subjects: 112
Study 24463121 — intervention group
Group type: COMPARATOR
Intervention: Control group (with medications only)
Number of subjects: 112
Study 22113064 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 fatty acid‐enriched emulsion (Lipoplus; study group, n = 32)
Number of subjects: 64
Study 22113064 — intervention group
Group type: COMPARATOR
Intervention: medium‐chain triacylglycerols/long‐chain triacylglycerols (Lipofundin; control group, n = 32)
Number of subjects: 64
Study 20844992 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive urodynamic tests
Number of subjects: 41
Study 17627191 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS)
Number of subjects: 20
Study 17627191 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care supplemented by use of a CGMS
Number of subjects: 20
Study 17627191 — intervention group
Group type: COMPARATOR
Intervention: Standard care for diabetes
Number of subjects: 20
Study 15608037 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (0.25 mg of cetrorelix daily starting on day 6 of stimulation)
Number of subjects: 66
Study 15608037 — intervention group
Group type: COMPARATOR
Intervention: Long GnRH agonist protocol (600 microg of buserelin acetate daily starting in the mid-luteal phase of the preceding cycle)
Number of subjects: 66
Study 15608037 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 66
Study 15608037 — intervention group
Group type: COMPARATOR
Intervention: Long GnRH agonist protocol
Number of subjects: 66
Study 12794818 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide (100 mg/day for 3 days, then 10 mg/day or 20 mg/day thereafter)
Number of subjects: 214
Study 10520056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 42
Study 7661113 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation sample (n = 151)
Number of subjects: 206
Study 7661113 — intervention group
Group type: COMPARATOR
Intervention: Validation sample (n = 55)
Number of subjects: 206
Study 1710395 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched chain‐enriched amino acid mixture (BCAA = 49.4%)
Number of subjects: 16
Study 1710395 — intervention group
Group type: COMPARATOR
Intervention: Standard amino acid infusion (BCAAs = 15.5%)
Number of subjects: 16
Study 1710395 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine intake
Number of subjects: 16
Study 1710395 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine clearance
Number of subjects: 16
Study 7425963 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily Beclomethasone dipropionate (BDP) treatment
Number of subjects: 0
Study 7425963 — intervention group
Group type: COMPARATOR
Intervention: Four times daily Beclomethasone dipropionate (BDP) treatment
Number of subjects: 0
Study 29401197 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) performing neuromuscular warm-up exercises (n = 12)
Number of subjects: 24
Study 29401197 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) involved in a standard warm-up (n = 12)
Number of subjects: 24
Study 29401197 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG)
Number of subjects: 24
Study 29401197 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 24
Study 26546010 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bed motion
Number of subjects: 68
Study 26546010 — intervention group
Group type: COMPARATOR
Intervention: Step-and-shoot
Number of subjects: 68
Study 26546010 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 68
Study 23839319 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mcg/kg/min (GROUP A)
Number of subjects: 228
Study 23839319 — intervention group
Group type: COMPARATOR
Intervention: 0.1 µg/kg/min (GROUP B)
Number of subjects: 228
Study 22828481 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-824-moxifloxacin-pyrazinamide (n=13)
Number of subjects: 66
Study 22828481 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline (n=14)
Number of subjects: 66
Study 22828481 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline-pyrazinamide (n=15)
Number of subjects: 66
Study 22828481 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline-PA-824 (n=14)
Number of subjects: 66
Study 22828481 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-824-pyrazinamide (n=14)
Number of subjects: 66
Study 22828481 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (n=10)
Number of subjects: 66
Study 19892499 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen hydrolysates (CH) 10g/day for 24 weeks
Number of subjects: 71
Study 19892499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 18306155 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared device with contact cooling (Titan, Cutera, Brisbane, CA)
Number of subjects: 13
Study 18306155 — intervention group
Group type: COMPARATOR
Intervention: Untreated side (control)
Number of subjects: 13
Study 15830983 — intervention group
Group type: EXPERIMENTAL
Intervention: Disc Coablation
Number of subjects: 100
Study 15830983 — intervention group
Group type: COMPARATOR
Intervention: Epidural Injection of Steroids
Number of subjects: 100
Study 12061355 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training regimen (EG1) - 3 sessions per week, 25-35 min per session at intensity >80% of maximal heart rate
Number of subjects: 84
Study 12061355 — intervention group
Group type: COMPARATOR
Intervention: Endurance training regimen (EG2) - 2 sessions per week, 15-20 min per session at intensity >80% of maximal heart rate
Number of subjects: 84
Study 12061355 — intervention group
Group type: COMPARATOR
Intervention: Control group - no training regimen
Number of subjects: 84
Study 10051289 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/d)
Number of subjects: 33
Study 10051289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 7670117 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive therapy based on polymerase chain reaction (PCR) technique
Number of subjects: 71
Study 7670117 — intervention group
Group type: COMPARATOR
Intervention: Culture assays
Number of subjects: 71
Study 1688039 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol (200 mg bd orally for 1 month)
Number of subjects: 11
Study 1688039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7259982 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone emollient cream 0.25% applied twice daily
Number of subjects: 22
Study 7259982 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 17-valerate 0.1% cream applied twice daily
Number of subjects: 22
Study 7259982 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone emollient cream
Number of subjects: 22
Study 31200708 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration resin plus fluoride
Number of subjects: 120
Study 31200708 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration resin plus CPP-ACP
Number of subjects: 120
Study 31200708 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration resin
Number of subjects: 120
Study 31200708 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP plus fluoride
Number of subjects: 120
Study 31200708 — intervention group
Group type: COMPARATOR
Intervention: Irradiation control
Number of subjects: 120
Study 31200708 — intervention group
Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 120
Study 31200708 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation + fluoride
Number of subjects: 120
Study 31200708 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation + CPP-ACP
Number of subjects: 120
Study 31200708 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation + CPP-ACP + fluoride
Number of subjects: 120
Study 31200708 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation + infiltration resin
Number of subjects: 120
Study 31200708 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation + infiltration resin + fluoride
Number of subjects: 120
Study 31200708 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation + infiltration resin + CPP-ACP
Number of subjects: 120
Study 29237441 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan treatment
Number of subjects: 24
Study 29237441 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 24
Study 25660917 — intervention group
Group type: COMPARATOR
Intervention: 1 to 2.4 hours of jogging per week
Number of subjects: 5048
Study 25660917 — intervention group
Group type: COMPARATOR
Intervention: Jogging frequency of 2 to 3 times per week
Number of subjects: 5048
Study 25660917 — intervention group
Group type: COMPARATOR
Intervention: Jogging frequency of ≤1 time per week
Number of subjects: 5048
Study 25660917 — intervention group
Group type: COMPARATOR
Intervention: Slow jogging pace
Number of subjects: 5048
Study 25660917 — intervention group
Group type: COMPARATOR
Intervention: Average jogging pace
Number of subjects: 5048
Study 25660917 — intervention group
Group type: COMPARATOR
Intervention: Light joggers
Number of subjects: 5048
Study 25660917 — intervention group
Group type: COMPARATOR
Intervention: Moderate joggers
Number of subjects: 5048
Study 25660917 — intervention group
Group type: COMPARATOR
Intervention: Strenuous joggers
Number of subjects: 5048
Study 23569140 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine treatment with pelvic floor exercises for 24 weeks
Number of subjects: 47
Study 23569140 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (ultrasonography, short wave diathermy and lumbar strengthening exercises) for 24 weeks
Number of subjects: 47
Study 21991949 — intervention group
Group type: EXPERIMENTAL
Intervention: AC-T plus trastuzumab
Number of subjects: 3222
Study 21991949 — intervention group
Group type: EXPERIMENTAL
Intervention: TCH
Number of subjects: 3222
Study 21991949 — intervention group
Group type: COMPARATOR
Intervention: AC-T
Number of subjects: 3222
Study 19422627 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.82 g/kg)
Number of subjects: 54
Study 19422627 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 54
Study 16920764 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration >=100 ms
Number of subjects: 562
Study 16920764 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration >=120 ms
Number of subjects: 562
Study 15274384 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta, 30,000 IU per week in three divided doses, with iron supplementation when needed.
Number of subjects: 29
Study 11762790 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate (2 weeks)
Number of subjects: 14
Study 11762790 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (2 weeks)
Number of subjects: 14
Study 11762790 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate and sodium bicarbonate
Number of subjects: 14
Study 9405902 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatrist care (education and primary prevention measures)
Number of subjects: 733
Study 9405902 — intervention group
Group type: COMPARATOR
Intervention: Control group (written instructions only)
Number of subjects: 733
Study 8010420 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric lidocaine 5% solution in a single bolus of 75 mg
Number of subjects: 55
Study 8010420 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric lidocaine 2.5% solution in increments of 25 mg (maximum of three doses)
Number of subjects: 55
Study 8010420 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated doses of 50 mg (n = 15)
Number of subjects: 55
Study 8010420 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated doses of 75 mg (n = 15)
Number of subjects: 55
Study 8010420 — intervention group
Group type: COMPARATOR
Intervention: Titrated doses (overall)
Number of subjects: 55
Study 8010420 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (SD, TD50, TD75)
Number of subjects: 55
Study 2909593 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin/mineral supplement
Number of subjects: 49
Study 2909593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 2909593 — intervention group
Group type: COMPARATOR
Intervention: No treatment (adequate diet)
Number of subjects: 49
Study 2909593 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal menses
Number of subjects: 49
Study 2909593 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI less than 19.0
Number of subjects: 49
Study 31296256 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of TGFβ blocking antibody fresolimumab (10 mg/kg)
Number of subjects: 15
Study 31296256 — intervention group
Group type: COMPARATOR
Intervention: Lower dose of TGFβ blocking antibody fresolimumab (1 mg/kg)
Number of subjects: 15
Study 31296256 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with fresolimumab
Number of subjects: 15
Study 31296256 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro PD-1 blockade
Number of subjects: 15
Study 31296256 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline T cell functionality
Number of subjects: 15
Study 26135067 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 160
Study 26135067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 24244395 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved salt-restriction spoon and health education
Number of subjects: 403
Study 24244395 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 403
Study 21146229 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg quarterly
Number of subjects: 353
Study 21146229 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg quarterly
Number of subjects: 353
Study 21146229 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg monthly
Number of subjects: 353
Study 21146229 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg quarterly and 0.5 mg quarterly
Number of subjects: 353
Study 19034249 — intervention group
Group type: COMPARATOR
Intervention: 0.5% plain bupivacaine
Number of subjects: 50
Study 19034249 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 50
Study 19088594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation-based training program (ECMO Sim)
Number of subjects: 9
Study 14622685 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl with local heat applied for 4 hours and again for 1 hour at 24 hours (Session B)
Number of subjects: 10
Study 14622685 — intervention group
Group type: COMPARATOR
Intervention: Transdermal fentanyl without local heat (Session A)
Number of subjects: 10
Study 14622685 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl with heat applied for 15 minutes at 12 and 16 hours (Session C)
Number of subjects: 10
Study 14622685 — intervention group
Group type: COMPARATOR
Intervention: Transdermal fentanyl without heat (Session A)
Number of subjects: 10
Study 10890611 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 32
Study 10890611 — intervention group
Group type: COMPARATOR
Intervention: Control (ventilator therapy without inhaled nitric oxide)
Number of subjects: 32
Study 9263774 — intervention group
Group type: EXPERIMENTAL
Intervention: AB0 blood group distribution
Number of subjects: 2988
Study 9263774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lewis blood group distribution
Number of subjects: 2988
Study 9263774 — intervention group
Group type: EXPERIMENTAL
Intervention: Le (a+b‐) donors (non‐secretors)
Number of subjects: 2988
Study 9263774 — intervention group
Group type: EXPERIMENTAL
Intervention: Le (a‐b+) frequency
Number of subjects: 2988
Study 1702235 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin
Number of subjects: 245
Study 1702235 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin and graded compression stockings
Number of subjects: 245
Study 1702235 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran and graded compression stockings
Number of subjects: 245
Study 6191263 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate, CCNU and bleomycin (ECB)
Number of subjects: 46
Study 6191263 — intervention group
Group type: COMPARATOR
Intervention: CCNU and bleomycin (CB)
Number of subjects: 46
Study 30885809 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based training program - Massachusetts Eye & Ear ROP Trainer
Number of subjects: 60
Study 30885809 — intervention group
Group type: COMPARATOR
Intervention: Standard print material on ROP (Control)
Number of subjects: 60
Study 28287046 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 18
Study 28287046 — intervention group
Group type: COMPARATOR
Intervention: No tap (NT)
Number of subjects: 18
Study 28287046 — intervention group
Group type: COMPARATOR
Intervention: Placebo tap (PT)
Number of subjects: 18
Study 26325246 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU vitamin D3/day
Number of subjects: 55
Study 26325246 — intervention group
Group type: COMPARATOR
Intervention: 800 IU vitamin D3/day
Number of subjects: 55
Study 26325246 — intervention group
Group type: COMPARATOR
Intervention: 1,200 IU vitamin D3/day
Number of subjects: 55
Study 24481910 — intervention group
Group type: EXPERIMENTAL
Intervention: ranolazine
Number of subjects: 6543
Study 24481910 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6543
Study 21573819 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sulphate‐bicarbonate‐calcium mineral water bath
Number of subjects: 60
Study 21573819 — intervention group
Group type: COMPARATOR
Intervention: Regular outpatient care routine (Control)
Number of subjects: 60
Study 19087001 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon's anaesthesia
Number of subjects: 50
Study 19087001 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anaesthesia
Number of subjects: 50
Study 17307426 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg once daily
Number of subjects: 92
Study 17307426 — intervention group
Group type: COMPARATOR
Intervention: metformin 850 mg twice daily
Number of subjects: 92
Study 14985866 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-DTPA excretion method
Number of subjects: 20